---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-003329"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2025-09-15T23:59:59+00:00"
generated_at: "2026-05-17T06:40:48.861726+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Silexion regains Nasdaq compliance with $9.4M equity after capital raise

## Summary
- Issued 450,000 shares to sponsor upon converting $1.8M of convertible note at $4.00/share; remaining $1.6M outstanding.
- Shareholders' equity rose to ~$9.4M from -$0.7M at July 31, 2025, after four transactions.
- Company affirms compliance with Nasdaq Capital Market equity requirement of $2.5M and expects long-term compliance.
- Gross proceeds from September 2025 public offering: ~$6.0M from sale of shares/pre-funded warrants and warrants.
- Warrant exercise inducement in August 2025 generated ~$1.8M gross proceeds.

## SEC filing metadata
- accession: 0001178913-25-003329
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2025-09-15T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891325003329/0001178913-25-003329-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891325003329/zk2533784.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-003329
- JSON: https://secwatch.observer/filing/0001178913-25-003329.json
- Plain text: https://secwatch.observer/filing/0001178913-25-003329.txt

## Key facts
- Equity Issuances
  Silexion Therapeutics Corp issued 450,000 ordinary shares of common stock to Moringa Sponsor, LP for $1.8 million of the outstanding amount under the Amended and Restated Promissory Note.
  - Security: common stock
  - Shares: 450,000 ordinary shares
  - Purchaser: Moringa Sponsor, LP
  - Consideration: $1.8 million of the outstanding amount under the Amended and Restated Promissory Note
  source text: On September 15, 2025, Silexion Therapeutics Corp, a Cayman Islands exempted company (“ Silexion ” or the “ Company ”) issued 450,000 ordinary shares, par value $0.0135 per share, of Silexion (“ ordinary shares ”), to Moringa Sponsor, LP (the “ Sponsor ”) upon conversion by Silexion of an aggregate of $1.8 million of the outstanding amount under the Amended and Restated Promissory Note, dated August 15, 2024, in an original principal amount of $3.4 million (the “ Sponsor Convertible Note ”), issued by Silexion to the Sponsor.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2022416/000117891325003329/0001178913-25-003329-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.